Summary:
- Novartis, a leading pharmaceutical company, reported strong financial performance in Q3 2024, with a 10% increase in sales and a 20% growth in core operating income.
- The company achieved important innovation milestones, including the advancement of its pipeline of novel therapies and the approval of new products.
- Novartis has raised its full-year 2024 guidance, reflecting its continued momentum and confidence in its ability to deliver sustainable growth and value for its stakeholders.